Therefore, we have high expectations that the Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (NCT03117751) clinical trial which is a prospective study and will hopefully further clarify the role of CEP72 in predilection toward VIPN, and its usefulness as a biomarker in clinical practice [26]. The gene discussed is CEP72; the disease is acute lymphoblastic leukemia.